The Outcome of the Intravesical BCG Treatment in Naive Positive Tuberculin Skin Test Non-Muscle Invasive Bladder Cancer Patients
Keywords:
BCG (Bacillus Calmette-Guerin), Bladder cancer, PPD (Purified Protein Derivative)Abstract
Purpose: To study one-year outcome of intravesical Bacillus Calmette-Guerin (BCG) treatment in patients with non-muscle invasive bladder cancers.
Materials and Methods: From May 2008 to August 2009, 12 patients with primary non-muscle invasive bladder cancers were treated with TUR-BT followed by 6 weekly induction courses and maintenance of 3-, 6- and 12-month intravesical BCG treatment for recurrent tumor prophylaxis. Patients were divided into 2 groups: 7 with negative Purified Protein Derivative (PPD) skin test and 5 with positive skin test prior to the intravesical BCG treatment.
Results: There was only one recurrent patient in the negative PPD skin test group and 3 patients in positive PPD skin test had recurrence tumors.
Conclusions: In patients with primary naïve positive PPD skin test, the intra-vesical chemotherapy should be considered for treatment of primary non-muscle invasive bladder cancers instead of BCG.
References
2. Camacho F, Pinsky C, Kerr D, Whitmore W, Oettgen H. Treatment of superficial bladder cancer with intravesical BCG. Proc Amer Ass Cancer Res Amer Soc Clin Oncol 1980; 21:359 (Abstract C-160).
3. Lamm, DL, Thor DE, Stogdill VD, Radwin HM. Bladder cancer immunotherapy. J Urol 1982;128:931.
4. Brosman SA. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1982;128:27.
5. Morales A, Ersil A. Prophylaxis of recurrent bladder cancer with bacillus Calmette-Guerin. In : Cancer of the Genitourinary Tract. Edited by Johnson DE. and Samuels ML. New York: Raven Press; 1979. p. 121-32.
6. Douville Y, Pelouze G, Roy R, Charrois R, Kibrite A, Martin M. et al. Recurrent bladder papillomata treated with bacillus Calmette-Guerin : a preliminary report (phase I trial). Cancer Treat Rep 1978;62:552.
7. Morales A, Ottenhof P, Emerson L. Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette- Guerin. J Urol 1981;125:649.
8. Morales A. Treatment of carcinoma in situ of the bladder with BCG, a phase II trial. Cancer Immunol. Immunother 1980;9:69.
9. Herr HW, Pinsky CM. Whitmore WF. Oettgen HF, Melamed MR. Effects of intravesical bacillus Calmette Guerin (BCG) on carcinoma in situ of the bladder. Cancer 1983;51:1323.
10. Kelly DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, et al. Prognostic value of purified protein derivative skin testand granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol 1986; 135: 268.
11. Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, et al. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer effect of bacillus Calmette-Guerin viability on treatment results. J Urol 1985;134:48-53.
12. Lamm DL. Bacillus Calmette-Gurin immunotherapy for bladder cancer. J Urol 1985;134:40.
13. Badalament RA. Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 1987;5:441.
14. Wein AJ, ed. Campbell-Walsh Urology. 9th ed. Philadelphia: Saunders Elsevier; 2007. p. 2455-7.
15. Lamm DL, Thor DE, Stogdill VD, Radwin HM. Bladder cancer immunotherapy. J Urol 1982;128:931.
16. American Thoracic Society/CDC official statement. The tuberculosis skin test, 1981. Amer Rev Resp Dis 1981;124:3.
Downloads
Published
How to Cite
Issue
Section
License
Articles must be contributed solely to The Thai Journal of Surgery and when published become the property of the Royal College of Surgeons of Thailand. The Royal College of Surgeons of Thailand reserves copyright on all published materials and such materials may not be reproduced in any form without the written permission.
